POXEL.PA +67% on 2.87M volume 29 Jan 2026: Poxel S.A. EURONEXT 0.54 EUR target

The POXEL.PA stock surged 67.36% to €0.40 on heavy trading, with volume hitting 2,868,939 shares at market close on 29 Jan 2026. The move pushed price well above the 50-day average of €0.24 and beat the 200-day average near €0.39. We view this as a high-volume mover on EURONEXT in Europe. Meyka AI provided the real-time data used in this market analysis platform note.

POXEL.PA stock: Price action and volume surge

POXEL.PA stock rose from a previous close of €0.24 to €0.40 today. The session high was €0.4185 and the low was €0.2445. Trading volume of 2,868,939 versus an average of 197,773 shows strong investor interest. The one-day change percentage was 67.36%, signalling abnormal activity relative to normal trading.

POXEL.PA stock: Financials and valuation

Poxel S.A. reports EPS of -€0.26 and a negative P/E of -0.93. Market capitalisation stands at €13,020,004 with 53,690,737 shares outstanding. Price-to-sales is 1.70 and EV/Revenue reads 10.33. The company has a current ratio near 0.78, indicating tight short-term liquidity.

POXEL.PA stock: Clinical pipeline and news drivers

Poxel focuses on metabolic and liver therapies, led by Imeglimin and PXL770. Pipeline milestones and regulatory updates typically drive big moves in this biotechnology stock. No new company press release appears in the provided feed, so today’s jump likely reflects market positioning or speculative flows around upcoming catalysts.

POXEL.PA stock: Technicals and liquidity signals

Short-term indicators show momentum: RSI 56.49 and CCI 233.55. The 50-day average price is €0.24 and the 200-day average is €0.39. On‑balance volume sits negative, but the spike in traded shares improves intra-day liquidity and narrows bid-ask friction for active traders.

POXEL.PA stock: Analyst view, Meyka grade and model forecast

Meyka AI rates POXEL.PA with a score out of 100: 60.91 | Grade B | HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €0.15, a quarterly target of €0.54, and a yearly projection of €0.2642. Compared with the current €0.40, the quarterly target implies an upside of 35.00%, while the yearly model implies a downside of -33.95%. Forecasts are model-based projections and not guarantees.

POXEL.PA stock: Risks, catalysts and sector context

Key risks include cash constraints, trial outcomes, and regulatory delays. Poxel’s enterprise value of €79,077,004 implies high funding reliance. Catalysts include Phase III readouts and partnering updates. The healthcare sector in Europe has averaged positive YTD performance, but biotech remains high beta and event-driven. For broader market context see coverage on global flows and sector moves source and technology sector drivers source. Refer to the Meyka stock page for live ticks Meyka POXEL.PA.

Final Thoughts

POXEL.PA stock was a clear high-volume mover at market close on 29 Jan 2026, rising to €0.40 on 2,868,939 shares. The rally pushed price above short-term averages, but fundamentals remain mixed. Earnings and cash metrics show negative EPS of -€0.26 and a weak current ratio of 0.78, which raise funding risk. Meyka AI’s forecast model projects a near-term target at €0.54, implying 35.00% upside from today’s price, and a 12‑month model price of €0.2642, implying -33.95% downside. Investors should weigh the event-driven upside from clinical milestones against funding and regulatory risk. These model outputs and the Meyka grade inform tactical action but are not guarantees. We track catalysts and will update this POXEL.PA stock analysis as news and filings arrive.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.